)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Lärkberget
Lärkberget (LARK) investor relations material
Lärkberget H1 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.H1 2026 earnings summary20 Aug, 2026
Executive summary
Focus during H1 2026 was on consolidating and stabilizing after a strategic shift to a pure investment company model, emphasizing responsible management of holdings and cost control.
NAXS remains a core portfolio holding, providing significant dividend income and influencing NAV development.
A planned rights issue of approximately 14.9 MSEK was evaluated but ultimately canceled due to market conditions.
A new board was elected at the AGM, initiating a review of strategic alternatives to maximize shareholder value.
Financial highlights
Result after financial items for Jan–Jun 2026 was 1,221 TSEK, a marked improvement from -12,339 TSEK in the same period 2025, mainly due to lower costs and higher dividend and interest income.
Net sales for the period were 252 TSEK, with total income including dividends and interest at 3,248 TSEK.
Cash flow for the period was 518 TSEK, compared to -13,466 TSEK in H1 2025.
Cash and cash equivalents at period end were 3,112 TSEK (60,282 TSEK at H1 2025).
Outlook and guidance
Ongoing review of strategic alternatives to enhance shareholder value, with further updates expected in H2 2026.
The company’s financial position and existing investments are considered sufficient to finance ongoing operations.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Lärkberget
- Webinar agenda: CG01 strategy, gene therapy focus and cost reduction.LARK
Status Update - Shifted to investment focus, posted positive H2, and grew NAV per share to 3.08 SEK.LARKQ4 2025
- Strategic shift to investment focus completed; strong cash, first investments imminent.LARKQ2 2025
- Strategic Partner A/S proposes a new board led by Luca Di Stefano for CombiGene.LARKInvestor Update
- Gene therapy focus sharpened, COZY prioritized, and cost cuts extend liquidity to 2026.LARKQ3 2024
- CG01 rights regained, CGT2 discontinued, COZY advanced; sales and cash declined year-over-year.LARKQ2 2024
- CombiGene halts R&D, posts SEK 44.9m loss, and shifts focus to investments or dividends.LARKQ4 2024
Next Lärkberget earnings date
H2 202611 Feb, 2027
Lärkberget
Next Lärkberget earnings date
H2 202611 Feb, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Lärkberget AB is a biotechnology company based in Sweden, focusing on developing gene therapies for severe neurological and psychiatric disorders. The company's primary projects include treatments for drug-resistant focal epilepsy and severe chronic pain. Lärkberget utilizes gene therapy vectors, specifically adeno-associated virus (AAV) vectors, to deliver therapeutic genes. The company operates in collaboration with external research entities and contract research organizations to develop its therapeutic candidates from preclinical stages to proof of concept, aiming for subsequent commercialization through strategic partnerships. The company is headquartered in Lidingö, Sweden, and its shares are listed on the Nasdaq Stockholm.